With a pipeline from Gerngross’ Adimab, Arsanis hunts a $58M IPO for antibody development work
After burning through slightly more than $81 million, a biotech co-founded by Adimab’s Tillman Gerngross has pencilled in a $57.5 million raise from an IPO designed to get its mid-stage pneumonia fighting antibody through Phase II and down the road to a potential approval.
Arsanis got its pipeline, including its lead program for ASN100 and preclinical RSV antibodies, from Gerngross’ Adimab, along with cash from a broad syndicate of investors, a loan from Silicon Valley Bank and a grant-plus-investment from the Gates Foundation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.